| Brian Jacob Johnson, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Brian Jacob Johnson |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 5 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689134710 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 30256 (Minnesota) | Secondary |
| 207Y00000X | Otolaryngology | 68164 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
| Mayo Clinic Health System-southwest Minnesota Region | 4688585771 | 533 |
News Archive
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer's spread.
Post-traumatic stress disorder (PTSD) more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease, according to research presented at the American Heart Association's Scientific Sessions 2010.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer's spread.
Post-traumatic stress disorder (PTSD) more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease, according to research presented at the American Heart Association's Scientific Sessions 2010.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer's spread.
Post-traumatic stress disorder (PTSD) more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease, according to research presented at the American Heart Association's Scientific Sessions 2010.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer's spread.
Post-traumatic stress disorder (PTSD) more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease, according to research presented at the American Heart Association's Scientific Sessions 2010.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer's spread.
Post-traumatic stress disorder (PTSD) more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease, according to research presented at the American Heart Association's Scientific Sessions 2010.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brian Jacob Johnson, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Brian Jacob Johnson, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
Scientists at the University of Toronto's Leslie Dan Faculty of Pharmacy have seen remarkable success combining tumor modulating nanoparticles with doxorubicin to enhance chemotherapy response in pre-clinical model breast cancer.
A major challenge for cancer biologists is figuring out which among the hundreds of genetic mutations found in a cancer cell are most important for driving the cancer's spread.
Post-traumatic stress disorder (PTSD) more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease, according to research presented at the American Heart Association's Scientific Sessions 2010.
Stereotaxis, Inc. today reported financial results for the first quarter ended March 31, 2010 highlighted by recurring revenue and gross margin achieving record levels while operating losses continued to decline. In addition, the Company reported that its efforts to drive clinical adoption within the U.S. market are favorably impacting utilization rates.
› Verified 1 days ago
Dr. Kendall Krystyna Tasche, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Charles Wayne Beatty, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Jan L Kasperbauer, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Nicolas Ernest Maragos, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Laura J Orvidas, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Nicholas Reed Randall, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Lazaro Rafael Peraza, MD Otolaryngology Medicare: May Accept Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |